Translational Development Acquisition Corp.
TDAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $178,538 | $177,158 | $40,824 | $40,541 |
| - Cash | $47 | $35 | $207 | $438 |
| + Debt | $0 | $5,281 | $6,213 | $6,110,777,000 |
| Enterprise Value | $178,490 | $182,403 | $46,830 | $6,110,817,102 |
| Revenue | $0 | $192 | $224 | $0 |
| % Growth | -100% | -14.3% | – | – |
| Gross Profit | $0 | $29 | $61 | $0 |
| % Margin | – | 15.1% | 27.4% | – |
| EBITDA | $0 | -$221 | -$347 | -$135 |
| % Margin | – | -115.3% | -155.2% | – |
| Net Income | $1,660 | $1,623 | $1,483 | -$8 |
| % Margin | – | 846.5% | 662.5% | – |
| EPS Diluted | 0.08 | 0.074 | 0.37 | -0.002 |
| % Growth | 8% | -80% | 24,766.7% | – |
| Operating Cash Flow | -$1,245 | -$171 | -$232 | -$811 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,245 | -$171 | -$232 | -$811 |